Marissa Hill Daley
Subscribe to Marissa Hill Daley's PostsMarissa Hill Daley focuses her practice on healthcare and US Food & Drug Administration (FDA) matters, including advising clients on regulatory compliance, government and internal investigations, and FDA marketing requirements. Marissa also defends clients against whistleblower qui tam suits that involve the False Claims Act and the Anti-Kickback Statute.Read Marissa Hill Daley's full bio.
DOJ Proposes to Reschedule Marijuana (Cannabis) to Schedule III
By James R. Ravitz, Alva C. Mather, Paul S. Gadiock, Deepika Raj, Marissa Hill Daley and Karis Jackson on Jun 3, 2024
Posted In Cannabis, Food Safety and FDA, Hemp-Derived Beverages, THC Beverages
On May 21, 2024, the US Department of Justice (DOJ) published the highly anticipated notice of proposed rulemaking (NPRM) to reschedule marijuana (cannabis) from a Schedule I controlled substance to Schedule III, taking the first step to easing federal restrictions on cannabis and potentially opening up the door for further cannabis research and development. This regulatory change...
Continue Reading
